The P2 purinoceptors in prostate cancer

Purinergic Signal. 2023 Mar;19(1):255-263. doi: 10.1007/s11302-022-09874-2. Epub 2022 Jun 30.

Abstract

P2 purinoceptors are composed of ligand-gated ion channel type (P2X receptor) and G protein-coupled metabolite type (P2Y receptor). Both these receptors have played important roles in the prostate cancer microenvironment in recent years. P2X and P2Y receptors can contribute to prostate cancer's growth and invasiveness. However, the comprehensive mechanisms have yet to be identified. By summarizing the relevant studies, we believe that P2X and P2Y receptors play a dual role in cancer cell growth depending on the prostate cancer microenvironment and different downstream signalling pathways. We also summarized how different signalling pathways contribute to tumor invasiveness and metastasis through P2X and P2Y receptors, focusing on understanding the specific mechanisms led by P2X4, P2X7, and P2Y2. Statins may reduce and prevent tumor progression through P2X7 so that P2X purinergic receptors may have clinical implications in the management of prostate cancer. Furthermore, P2X7 receptors can aid in the early detection of prostate cancer. We hope that this review will provide new insights for future mechanistic and clinical investigations into the role of P2 purinergic receptors in prostate cancer.

Keywords: Akt; ERK1/2; P2 purinoceptors; P2XR; P2YR; Prostate cancer.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine Triphosphate
  • Humans
  • Male
  • Prostatic Neoplasms*
  • Receptors, Purinergic P2* / metabolism
  • Receptors, Purinergic P2X
  • Tumor Microenvironment

Substances

  • Receptors, Purinergic P2
  • Receptors, Purinergic P2X
  • Adenosine Triphosphate